Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt's Abuse Deterrent Oxycodone IR Narrowly Wins US FDA Panel Backing

Executive Summary

"Incremental" step forward is sufficient for product to be labeled as deterring abuse by nasal, but not intravenous route, advisory committee members conclude.
Advertisement

Related Content

US FDA Launches Study Of Prescriber Perceptions About Abuse-Deterrent Opioids
Recent And Upcoming FDA Advisory Committee Meetings
PMRS Continues Campaign Against Other Abuse Deterrent Opioid Products
Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel